{"id":"metadoxine-extended-release","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Gastrointestinal disturbance"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Metadoxine acts as a cofactor in the conversion of acetaldehyde to acetate, accelerating the detoxification pathway and reducing acetaldehyde-induced oxidative stress. It also enhances hepatic glutathione levels and reduces lipid peroxidation, providing cytoprotective effects in alcohol-related liver disease and acute alcohol intoxication.","oneSentence":"Metadoxine is a combination of pyridoxine (vitamin B6) and L-2-aminoethanol that enhances acetaldehyde metabolism and reduces its toxic accumulation in alcohol-related disorders.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:54:33.611Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute alcohol intoxication"},{"name":"Alcohol-related liver disease"},{"name":"Hangover symptoms"}]},"trialDetails":[{"nctId":"NCT00995085","phase":"PHASE1","title":"Efficacy Study of Metadoxine SR Formulation in Attention Deficit Hyperactivity Disorder (ADHD) Subjects","status":"COMPLETED","sponsor":"Alcobra Ltd.","startDate":"2009-10","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":43},{"nctId":"NCT02126995","phase":"PHASE2","title":"A 6-week, Study of MG01CI Low Dose and High Dose Compared With Placebo in Adults and Adolescents With Fragile X Syndrome","status":"COMPLETED","sponsor":"Alcobra Ltd.","startDate":"2014-06","conditions":"Fragile X Syndrome","enrollment":62},{"nctId":"NCT02189772","phase":"PHASE2","title":"Safety and Tolerability Study of Metadoxine Extended Release (MDX) (Previously Known as MG01CI) in PI-ADHD Adolescent Subjects","status":"COMPLETED","sponsor":"Alcobra Ltd.","startDate":"2014-08","conditions":"ADHD, Predominantly Inattentive Type","enrollment":83},{"nctId":"NCT01685281","phase":"PHASE2","title":"Study Comparing Two Doses of MG01CI and Placebo in Adults With Predominantly Inattentive Attention Deficit Hyperactivity Disorder","status":"COMPLETED","sponsor":"Alcobra Ltd.","startDate":"2013-08","conditions":"ADHD Predominantly Inattentive Type","enrollment":36},{"nctId":"NCT01243242","phase":"PHASE2","title":"Clinical Efficacy & Safety, of Metadoxine (MG01CI) Extended Release in Attention-Deficit Hyperactivity Disorder (ADHD)","status":"COMPLETED","sponsor":"Alcobra Ltd.","startDate":"2011-02","conditions":"ADHD","enrollment":120}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["MDX","Metadoxil","Abrixone","Metadoxine, Metadoxil","Abrixone, Metadoxil"],"phase":"marketed","status":"active","brandName":"Metadoxine extended release","genericName":"Metadoxine extended release","companyName":"Alcobra Ltd.","companyId":"alcobra-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Metadoxine is a combination of pyridoxine (vitamin B6) and L-2-aminoadipic acid that enhances acetaldehyde metabolism and reduces its toxic accumulation in alcohol-related disorders. Used for Alcohol use disorder with hepatic impairment, Alcoholic liver disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}